ATS Core Curriculum 2020

Adult Critical Care Medicine

Başak Çoruh, Susan Pasnick, Megan Acho, Geoffrey D. Bass, Cameron M. Baston, Mary Elizabeth Card, Alice Gallo de Moraes, Valerie E. M. Griffith, Amjad Kanj, Matthew J. Leveno, Dylan Lovin, Stephanie I. Maximous, Steven D. Pearson, R. Scott Stephens, Krysta S. Wolfe, Bishoy Zakhary, Jakob I. McSparron, and Margaret M. Hayes

1University of Washington, Seattle, Washington; 2MidCentral District Health Board, Palmerston North, New Zealand; 3University of Pittsburgh, Pittsburgh, Pennsylvania; 4University of Pennsylvania, Philadelphia, Pennsylvania; 5Johns Hopkins University, Baltimore, Maryland; 6Mayo Clinic Rochester, Rochester, Minnesota; 7Oregon Health and Science University, Portland, Oregon; 8University of Texas Southwestern, Dallas, Texas; 9University of Chicago, Chicago, Illinois; 10University of Michigan, Ann Arbor, Michigan; and 11Beth Israel Deaconess Medical Center, Boston, Massachusetts

ABSTRACT

The American Thoracic Society Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, medical critical care, and sleep medicine, in a 3- to 4-year recurring cycle of topics. These topics will be presented at the 2020 International Conference. Below is the adult critical care medicine core including complications of chemotherapy, acute-on-chronic liver failure, alcohol withdrawal syndrome, mechanical circulatory support, direct oral anticoagulants, upper gastrointestinal hemorrhage, and vasopressor selection.

Keywords:
core curriculum; critical care medicine; clinical review

KEY POINTS

• All classes of conventional chemotherapy and immunotherapy agents can be associated with life-threatening side effects, including pulmonary toxicity, neurotoxicity, and cardiotoxicity. The intensive care unit physician must be prepared to recognize and manage these toxicities in close collaboration with the treating oncologist.

• Prompt recognition and multidisciplinary management of acute-on-chronic liver failure and its triggering event(s) are crucial in preventing high short-term mortality and multiple organ failure.

• A severe alcohol withdrawal syndrome, like many critical illnesses, is best managed through early identification and prevention. Once manifest, first-line therapy for severe withdrawal remains benzodiazepines with varying degrees of evidence supporting phenobarbital, dexmedetomidine, and propofol as adjuncts.

• There are many mechanical circulatory support devices available that differ by ventricle supported, blood flow capability, and ability to incorporate an oxygenator for respiratory support.

(Received in original form February 6, 2020; accepted in final form August 28, 2020)

Correspondence and requests for reprints should be addressed to Başak Çoruh, M.D., University of Washington, 1959 North East Pacific Street, Box 356522, Seattle, WA 98195. E-mail: bcoruh@uw.edu.

ATS Scholar Vol 1, Iss 4, pp 436–455, 2020
Copyright © 2020 by the American Thoracic Society
DOI: 10.34197/ats-scholar.2020-0015RE
• In cases of life-threatening bleeding, direct oral anticoagulants should be discontinued and reversal of the anticoagulated state should be pursued; this may range from dialysis to administration of clotting factor products to agent-specific reversal drugs, where available.
• Successful management of upper gastrointestinal hemorrhage requires an interdisciplinary approach of hemodynamic stabilization, medical management, endoscopic intervention, and, in refractory cases, vascular procedures.
• Vaspressors are indicated when blood pressure and tissue perfusion remain insufficient following intravascular volume resuscitation; options include catecholamines, vasopressin, and angiotensin II.

The American Thoracic Society (ATS) Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, critical care, and sleep medicine, in a 3- or 4-year recurring cycle of topics. The 2020 course was intended for presentation in May during the annual International Conference. Because of the coronavirus disease (COVID-19) pandemic, the annual conference was canceled, and the talks are available as part of the ATS 2020 Virtual Meeting. The following is a concise review of the critical care topics covered in the 2020 ATS Core Curriculum.

COMPLICATIONS OF CHEMOTHERAPY

Mary Elizabeth Card and R. Scott Stephens

The mainstays of cancer treatment are conventional chemotherapy and, increasingly, immunotherapy and immune effector cell therapy. These therapies are associated with life-threatening side effects, such as pulmonary toxicity, neurotoxicity, and cardiotoxicity (Figure 1).

GENERALIZED TOXICITY

Several chemotherapy agents can induce toxicity immediately after administration.
Patients with acute promyelocytic leukemia treated with all-trans retinoic acid (ATRA) and arsenic trioxide can rapidly develop ATRA syndrome, a severe inflammatory response caused by rapid differentiation of myeloid cells. Presentation includes fever and capillary leak syndrome resulting in hypotension and pulmonary edema. Treatment requires rapid initiation of high-dose steroids (1, 2). In general, ATRA/arsenic trioxide should be continued. ATRA syndrome is difficult to distinguish from septic shock; empiric antibiotics should be administered. Cytarabine syndrome, seen with cytarabine-containing induction regimens for acute myeloid leukemia, can also present with capillary leak and hypotension. Treatment includes steroids and supportive care.

PULMONARY TOXICITY
Adverse events range from subacute shortness of breath to fulminant respiratory failure (1). Some agents, such as bleomycin and busulfan, are associated with predictable, dose-dependent toxicities, but many agents cause idiosyncratic effects. Diagnosis depends on presentation, chest imaging, and exclusion of alternative diagnoses. The offending agent should be discontinued, and steroids should be administered, although efficacy is limited. Steroid dose and duration are not well established; a generally accepted regimen is 0.5–1 mg/kg/d of prednisone (or equivalent) for 8–12 weeks (1).

NEUROTOXICITY
Life-threatening neurotoxicity includes posterior reversible leukoencephalopathy syndrome, seizures, cytarabine neurotoxicity, and encephalopathy (3, 4). Calcineurin inhibitors (e.g., tacrolimus, cyclosporine) are common precipitators of posterior reversible leukoencephalopathy syndrome (5), which presents with encephalopathy, seizures, hypertension, and magnetic resonance imaging abnormalities. The triggering agent should be discontinued and blood pressure controlled. High-dose busulfan, used in the conditioning regimen for hematopoietic stem cell transplant, causes seizures in up to 10% of patients. Ifosfamide can cause a stroke-like presentation with seizures, confusion, cerebellar dysfunction, and focal motor-sensory deficits, typically reversible with methylene blue. Cytarabine can also cause acute cerebellar toxicity, cerebral dysfunction, and seizures.

CARDIOTOXICITY
Cardiac toxicity, including acute coronary syndrome (ACS) and dilated cardiomyopathy leading to cardiogenic shock, is a leading cause of long-term morbidity and mortality in patients with cancer (6). ACS may be the result of chemotherapy-induced stress in the setting of preexistent risk factors, but some chemotherapeutic agents, most notably fluoropyrimidines and platinum-based agents, have been reported to trigger ACS (6). Treatment of ACS is complicated by the prevalence of coagulopathies and thrombocytopenia in this population. Anthracyclines (e.g., doxorubicin) are known to cause heart failure, which should be treated according to typical standards of care (6).

IMMUNOTHERAPY COMPLICATIONS
Immune checkpoint inhibitors (ICIs) are used to treat an increasing number of malignancies. ICIs can affect any organ system, with the most common immune-related adverse events (irAEs) being cutaneous, gastrointestinal, hepatic, endocrine, and pulmonary toxicities. Toxicities are graded on a scale of 1–4; grades 3–4 indicate severe or life-threatening reactions. Grade 3 or 4 cutaneous toxicities have an incidence of 1–3% and
include inflammatory dermatitis, bullous dermatoses, Stevens-Johnson syndrome/toxic epidermal necrolysis, and drug-induced hypersensitivity syndrome. High-grade gastrointestinal toxicity affects about 15% of patients, presents 5–10 weeks after ICI initiation, and includes severe colitis and acute liver failure. Endocrine toxicities include primary hypo-/hyperthyroidism, primary adrenal insufficiency, and hypophysitis. Severe pneumonitis is reported to occur in approximately 2% of patients treated with ICIs, although the true incidence may be higher. Patients typically present 2–24 months after ICI initiation with dyspnea, cough, fever, and chest pain and can develop fulminant respiratory failure. Chest computed tomography findings typically demonstrate ground-glass opacities.

Regardless of organ system involved, the diagnosis of irAEs remains one of exclusion. Initial treatment for grade 3 and 4 toxicities should include at least temporary cessation of immunotherapy and 1–2 mg/kg/d intravenous methylprednisolone, tapering over at least 4 weeks or based on symptom resolution. In steroid-refractory cases, other immunosuppressive agents (such as intravenous immunoglobulin, cyclophosphamide, mycophenolate mofetil, or infliximab) can be considered. For grade 4 irAEs, ICI treatment should be permanently discontinued. For grade 3 or less, the risks versus benefits of resuming ICIs must be weighed in consultation with an oncologist (7).

Chimeric antigen receptor T-cell therapy is yet another novel anticancer therapy. Common toxicities include cytokine release syndrome and immune effector neurotoxicity. Treatment for cytokine release syndrome consists of supportive care, with anti–interleukin 6 agents (e.g., tocilizumab, an anti–interleukin 6 monoclonal antibody) and steroids reserved for severe cases. In contrast, tocilizumab is ineffective in neurotoxicity, and steroids are the mainstay of therapy (8).

REFERENCES

1. Shannon VR. Cancer treatment-related lung injury. In: Nates JL, Price KJ, editors. Oncologic critical care. Cham, Switzerland: Springer, Cham; 2019. pp. 531–556.

2. Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019;133:1630–1643.

3. Bellamy C, Ball A. Life threatening toxicities of chemotherapies and immunomodulating medications. In: Decision support in medicine: critical care medicine. 2nd ed. Wilmington, DE: Decision Support in Medicine; 2017.

4. Rivera MJ, Do B, Bryan JC, Shigle TL, Patel R. Complications and toxicities associated with cancer therapies in the intensive care unit. In: Nates JL, Price KJ, editors. Oncologic critical care. Cham, Switzerland: Springer, Cham; 2019. pp. 201–227.

5. Thomas CR Jr, Stelzer KJ, Douglas JG, Koh WJ, Wood LV, Panicker R. Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II. J Natl Med Assoc 1994;86:839–852.

6. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Astegiano R, Galderisi M, et al.; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 2017;19:9–42.
ACUTE-ON-CHRONIC LIVER FAILURE
Amjad Kanj and Alice Gallo de Moraes

Acute-on-chronic liver failure (ACLF) refers to profound hepatic decompensation and organ failure in patients with preexisting liver disease. It is associated with high short-term mortality and requires prompt recognition and aggressive management (1). ACLF is often triggered by sepsis, gastrointestinal bleeding, or drugs/toxins. Severity largely depends on the host’s immune dysfunction and inflammatory response to the inciting event (2), which often cannot be identified (1). The management of ACLF is summarized in Table 1.

SEPSIS AND ACLF

Sepsis is a common trigger for ACLF. When suspected, an infectious workup including evaluation for spontaneous bacterial peritonitis must be performed (2). Antibiotics should be started immediately and tailored according to culture results and local resistance patterns. Empiric antifungal therapy should be considered in patients without clinical improvement after 48–72-hours of broad-spectrum antibiotics (2). Balanced crystalloids, such as lactated Ringer’s, are recommended for initial fluid resuscitation (3). Albumin is recommended in patients with spontaneous bacterial peritonitis and after large-volume paracentesis (4). Norepinephrine (NE) remains the preferred vasoactive drug and should be titrated for a mean arterial pressure of 60–65 mm Hg (2, 4).

ORGAN FAILURE IN ACLF

Extrahepatic organ failure is a hallmark of ACLF. The definitions of ACLF and organ failure vary among international societies, but the proposed management is similar (4, 5).

Renal Failure

Renal failure (RF) is the most frequent organ dysfunction in ACLF. Serum creatinine and, to a lesser extent, cystatin C overestimate renal function in ACLF. Urine output remains an early sensitive marker for RF. Management of RF depends on the etiology. In type 1 hepatorenal syndrome, vasoconstrictors and 25% albumin should be used. NE is the vasoconstrictor of choice when terlipressin is not available. Alternatively, the combination of octreotide, midodrine, and albumin may be used but should be switched to terlipressin or NE if kidney function fails to improve within 3 days. In patients with refractory volume overload and electrolyte imbalances, renal replacement therapy can be initiated until prognosis is determined (4).

Hepatic Encephalopathy

Hepatic encephalopathy is graded using the West Haven criteria; patients with grade 1 encephalopathy exhibit mild symptoms,
whereas those with grade 4 are comatose (3). Lactulose should be initiated and titrated to 2–3 bowel movements per day. Head imaging and electroencephalography should be considered to exclude structural abnormalities and seizures when encephalopathy is severe or when there is lack of response to treatment (4). Aspiration precautions are important in those at high risk. Endotracheal intubation is recommended for Glasgow Coma Scale <8, and short-acting, nonbenzodiazepine medications are preferred for sedation (4).

**Coagulation Dysfunction**

The impact of liver disease on coagulation is variable, and partial thromboplastin time (PTT), international normalized ratio (INR), fibrinogen level, and bleeding time

---

**Table 1. Management of ACLF, its triggers, and associated organ failure**

| ACLF | Management |
|------|------------|
| **Triggers** | |
| Sepsis | Sources: consider blood, urine, lung, ascitic fluid, and pleural fluid |
| | Fluids: 30 ml/kg LR or PlasmaLyte |
| | Antibiotics: empiric broad-spectrum + antifungals if no improvement |
| | Vasopressors: norepinephrine ± vasopressin and hydrocortisone |
| Gastrointestinal bleed | Blood products, antibiotic prophylaxis, octreotide, definitive therapy |
| Toxins (e.g., alcohol) | Abstinence ± steroids |
| **Organ failure** | |
| Renal failure | Suspected type 1 HRS: Albumin + terlipressin (not available in the United States) or NE, OR albumin + midodrine + octreotide |
| | RRT in nonresponders who are potential liver/kidney transplant candidates |
| | Nephrology consultation |
| Hepatic encephalopathy | Lactulose ± rifaximin |
| | Intubation if GCS <8 |
| | Aspiration precautions |
| Coagulopathy | Target Hb >7 mg/dl |
| | Target platelets >50 x10^9/L if bleeding or before minimally invasive procedures |
| | Target fibrinogen >1.5 g/L if bleeding or before surgery |
| **Other** | |
| Consultations | Hepatology consultation |
| | Palliative care consultation |
| | Early referral to a liver transplant center |

*Definition of abbreviations: ACLF = acute-on-chronic liver failure; GCS = Glasgow Coma Scale; Hb = hemoglobin; HRS = hepatorenal syndrome; LR = lactated Ringer’s; NE = norepinephrine; RRT = renal replacement therapy.*
do not accurately reflect the risk of bleeding. Venous thromboembolism prophylaxis should be considered in the absence of active bleeding. There is no role for prophylactic transfusion of blood products in patients with abnormal coagulation parameters who are not actively bleeding (5). Transfusion targets are listed in Table 1. Unlike disseminated intravascular coagulation, coagulopathy of liver failure presents with normal or elevated factor VIII level with no schistocytes on peripheral smear. Viscoelastic testing can assess coagulopathy, but its role outside liver transplantation and surgery remains controversial (5).

**PROGNOSIS OF ACLF**

The 28-day mortality from ACLF approaches 80% among patients with ≥3 organ failures, and early referral to a transplant center is recommended. Validated scores, such as the CLIF-C (Chronic Liver Failure Consortium) ACLF, help define futility of intensive care support (6). A palliative care approach should be considered in patients with ACLF who continue to deteriorate despite 3–7 days of intensive care support and for whom organ transplant is not an option (6).

**REFERENCES**

1. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al.; CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013;144:1426–1437, 1437, e1–1437, e9.

2. Simonetto DA, Piccolo Serafim I, Gallo de Moraes A, Gajic O, Kamath PS. Management of sepsis in patients with cirrhosis: current evidence and practical approach. *Hepatology* 2019;70:418–428.

3. Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al.; SMART Investigators and the Pragmatic Critical Care Research Group. Balanced crystalloids versus saline in critically ill adults. *N Engl J Med* 2018;378:829–839.

4. Nadim MK, Durand F, Kellum JA, Levitsky J, O’Leary JG, Karvellas CJ, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. *J Hepatol* 2016;64:717–735.

5. Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al.; APASL ACLF Research Consortium [AARC] for APASL ACLF working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. *Hepatol Int* 2019;13:353–390.

6. Karvellas CJ, Garcia-Lopez E, Fernandez J, Saliba F, Sy E, Jalan R, et al.; Chronic Liver Failure Consortium and European Foundation for the Study of Chronic Liver Failure. Dynamic prognostication in critically ill cirrhotic patients with multiorgan failure in ICUs in Europe and North America: a multicenter analysis. *Crit Care Med* 2018;46:1783–1791.

**MANAGEMENT OF ALCOHOL WITHDRAWAL SYNDROME**

**Dylan Lovin and Matthew J. Leveno**

Alcohol use disorder (AUD) affects 20–42% of hospitalized patients. Most hospitalized patients with AUD will not develop symptoms of withdrawal sufficient to warrant medications, but 5–10% of those that do will require critical care (1, 2). The four most common presentations of alcohol withdrawal are discussed below.
UNCOMPLICATED ALCOHOL WITHDRAWAL

Uncomplicated alcohol withdrawal, also called simple or minor withdrawal, typically occurs within 6–24 hours of last alcohol intake (Figure 2). It is characterized by agitation, insomnia, headache, tremor, nausea/vomiting, and autonomic hyperactivity. Importantly, patients with uncomplicated withdrawal have a preserved mental status. Symptom-triggered benzodiazepine (BZD) administration using a validated withdrawal assessment tool is the treatment of choice (3). Patients with uncomplicated withdrawal who are treated with BZDs are far less likely to develop delirium tremens (4).

ALCOHOL HALLUCINOSIS

Alcohol hallucinosis is characterized by visual, auditory, or tactile hallucinations that develop 12–24 hours after last alcohol intake (Figure 2). Patients have an awareness of their hallucinations, and their orientation and vital signs are generally normal.

ALCOHOL WITHDRAWAL SEIZURES

Alcohol withdrawal seizures occur in a minority of patients experiencing withdrawal and may be the first manifestation of withdrawal. They typically occur within 6–48 hours following last alcohol intake (Figure 2). Although alcohol withdrawal is a common cause of a new-onset seizure, the diagnosis of an alcohol-related seizure is one of exclusion (5). Alcohol withdrawal seizures are most often tonic-clonic and occur in self-limited clusters of 1–3 seizures. Focal seizures and status epilepticus are atypical. BZDs are first-line therapy. A single dose of lorazepam is often sufficient to prevent additional seizures (6). However, patients remain at risk for other withdrawal symptoms, and 30% will develop delirium tremens if untreated.

DELIRIUM TREMENS

Delirium tremens represents the most severe form of alcohol withdrawal. The signs and symptoms of delirium tremens include severe delirium, autonomic hyperactivity, and hallucinations. BZDs remain first-line therapy. Although there is no clear first choice of BZD, drugs with a rapid onset of action and a favorable pharmacokinetic profile for the individual patient are preferred. For patients that fail to respond adequately to BZDs, common adjuncts include propofol, dexmedetomidine, and phenobarbital (7). In the

---

Figure 2. Onset of alcohol withdrawal syndromes relative to last alcohol intake.
nonintubated patient, dexmedetomidine and phenobarbital are useful agents. With more than 100 years of clinical experience, low cost, and multiple favorable studies, phenobarbital appears to be the adjunct of choice (8).

REFERENCES
1. Maldonado JR, Sher Y, Ashouri JF, Hills-Evans K, Swendsen H, Lolak S, et al. The “Prediction of Alcohol Withdrawal Severity Scale” (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol 2014;48:375–390.

2. Victor M, Adams RD. The effect of alcohol on the nervous system. Res Publ Assoc Res Nerv Ment Dis 1953;32:526–573.

3. Ungur LA, Neuner B, John S, Wernecke K, Spies C. Prevention and therapy of alcohol withdrawal on intensive care units: systematic review of controlled trials. Alcohol Clin Exp Res 2013;37:675–686.

4. Foy A, March S, Drinkwater V. Use of an objective clinical scale in the assessment and management of alcohol withdrawal in a large general hospital. Alcohol Clin Exp Res 1988;12:360–364.

5. Bräthen G, Ben-Menachem E, Brodtkorb E, Galvin R, García-Monco JC, Halasz P, et al; EFNS Task Force. EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force. Eur J Neurol 2005;12:575–581.

6. D’Onofrio G, Rathlev NK, Ulrich AS, Fish SS, Freedland ES. Lorazepam for the prevention of recurrent seizures related to alcohol. N Engl J Med 1999;340:915–919.

7. Wong A, Benedict NJ, Kane-Gill SL. Multicenter evaluation of pharmacologic management and outcomes associated with severe resistant alcohol withdrawal. J Crit Care 2015;30:405–409.

8. Mo Y, Thomas MC, Karras GE Jr. Barbiturates for the treatment of alcohol withdrawal syndrome: a systematic review of clinical trials. J Crit Care 2016;32:101–107.

MECHANICAL CIRCULATORY SUPPORT
Valerie E. M. Griffeth and Bishoy Zakhary

CARDIOGENIC SHOCK
Cardiogenic shock (CS) is defined as a reduced cardiac index (typically <1.8 L/min · m²) with end-organ hypoperfusion and adequate filling pressures. Outcomes are poor, with in-hospital mortality greater than 50% (1). Although inotropic infusions are often first-line therapy, failure to reverse the shock state necessitates mechanical circulatory support (MCS). Early identification of patients with severe or persistent shock may facilitate early initiation of MCS and improve outcomes.

MECHANICAL CIRCULATORY SUPPORT DEVICES
The goals of MCS are to supplement native cardiac function and restore end-organ perfusion, decompress the failing ventricle, and increase coronary artery perfusion. Although devices differ in mechanism of action, the majority reduce ventricular preload and afterload while increasing perfusion to the systemic circulation. For patients with reversible or treatable etiologies of CS, this support can facilitate definitive treatment, such as coronary intervention in ischemic disease or ablation therapy in refractory arrhythmia.

Multiple devices are available to support the acutely failing heart. For patients with isolated left ventricular failure, options include the intraaortic balloon pump...
(IABP), Impella (Abiomed), TandemHeart (LivaNova), Centrimag (Thoratec), and venoarterial extracorporeal membrane oxygenation (VA ECMO). For patients with isolated right ventricular failure, options include Impella RP, Tandem Protek Duo (LivaNova), Centrimag, and VA ECMO. Biventricular failure can be supported with two independent devices or with VA ECMO. Of note, if cardiac dysfunction is accompanied by severe respiratory failure, VA ECMO, in which a pump is combined with a membrane oxygenator capable of oxygenation and decarboxylation of blood, is necessary.

In deciding which device is most appropriate, primary consideration is given to which ventricle is failing and how much additional blood flow is required to reverse the shock state. A summary of the devices, including ventricular support type and typical flow capabilities, is provided in Table 2.

**CLINICAL OUTCOMES**

Although MCS use has grown, randomized trials are limited and have not demonstrated improved survival. The IABP-SHOCK II (Intra-aortic Balloon Pump in Shock II) trial randomized patients with myocardial infarction with CS to IABP or medical therapy and did not find a 30-day mortality difference (3). The Impella and the TandemHeart have been compared with IABP in patients with CS after myocardial infarction, and despite improving cardiac output relative to the IABP, these devices have failed to demonstrate a mortality benefit (4, 5). A randomized trial evaluating the utility of VA ECMO in CS is planned (NCT02301819).
Despite the lack of trials demonstrating mortality benefit, studies support the efficacy of mechanical devices to reverse shock and bridge patients to recovery or to implantable devices (6, 7). Such improvements in hemodynamics likely fuel the continued use of these devices. As the technology continues to evolve, further studies will be needed to define the expanding role of these devices in the management of CS.

REFERENCES
1. Mandawat A, Rao SV. Percutaneous mechanical circulatory support devices in cardiogenic shock. *Circ Cardiovasc Interv* 2017;10:e004337.
2. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. *Catheter Cardiovasc Interv* 2019;94:29–37.
3. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al.; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 2012;367:1287–1296.
4. Seyfarth M, Sibbing D, Bauer I, Fröhlich G, Bott-Flügel L, Byrne R, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. *J Am Coll Cardiol* 2008;52:1584–1588.
5. Burkhoff D, Cohen H, Brunckhorst C, O’Neill WW; TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. *Am Heart J* 2006;152:469, e1–469, e8.
6. Lima B, Kale P, Gonzalez-Stawinski GV, Kuiper JJ, Carey S, Hall SA. Effectiveness and safety of the Impella 5.0 as a bridge to cardiac transplantation or durable left ventricular assist device. *Am J Cardiol* 2016;117:1622–1628.
7. Truby L, Mundy L, Kalesan B, Kirtane A, Colombo PC, Takeda K, et al. Contemporary outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock at a large tertiary care center. *ASAIO J* 2015;61:403–409.

DIRECT ORAL ANTICOAGULANTS

Megan Acho and Stephanie I. Maximous

Direct oral anticoagulants (DOACs) are increasingly used; thus, intensivists must be familiar with their mechanisms and pharmacology (Table 3) to better anticipate and manage potential complications. DOACs fall into one of two classes: 1) direct thrombin inhibitors, which block thrombin (factor IIa), preventing fibrinogen’s cleavage into fibrin and thus preventing clot formation, and 2) factor Xa inhibitors, which block the conversion of prothrombin into thrombin. The latter are easily recognized by the suffix “-xaban” or “-x-ban.”

CONSIDERATIONS FOR DOAC USE IN THE INTENSIVE CARE UNIT

Risk of clinically significant bleeding is of paramount concern when selecting DOACs in the intensive care unit. Intensivists often defer initiating DOAC therapy during critical illness, relying instead on agents with short half-lives that may be rapidly discontinued. Although several clinical trials demonstrate reduced risk of bleeding...
| Name                          | Indications                                                                 | Delivery   | Dose Adjustment or Avoidance Recommended for Renal Impairment? | Reversal | Other Considerations                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|------------|----------------------------------------------------------------|----------|--------------------------------------------------------------------------------------|
| Direct thrombin inhibitors    |                                                                             |            |                                                                |          |                                                                                      |
| Bivalirudin                   | Periprocedural in patients undergoing angioplasty or percutaneous coronary intervention | Intravenous | Yes                                                            | Hemodialysis | Monitor with aPTT                                                                    |
| Argatroban                    | Periprocedural in patients undergoing percutaneous coronary intervention    | Intravenous | No                                                             | None     | None                                                                                 |
|                               | HIT                                                                          |            |                                                                |          |                                                                                      |
|                               | HITT                                                                         |            |                                                                |          |                                                                                      |
| Dabigatran                    | VTE prophylaxis, treatment                                                  | Oral       | Yes                                                            | Idarucizumab (monoclonal antibody fragment that binds dabigatran) | Not approved in patients with mechanical valves |
|                               | VTE prophylaxis after knee and hip replacement                              | Requires BID dosing | Hemodialysis | Ecarin-based assays correlate with drug concentration |
|                               | Atrial fibrillation/flutter                                                  |            |                                                                |          | Interacts with inducers/inhibitors of P-glycoprotein |
|                               | —                                                                            |            |                                                                |          | Do not use in pregnancy                                                               |
| Factor Xa inhibitors          | VTE prophylaxis, treatment                                                  | Oral       | Yes                                                            | Andexanet alfa | Not approved in patients with mechanical valves |
| Apixaban                      | Atrial fibrillation/flutter                                                  | Requires BID dosing |                                                                |          | Not for use in pregnancy                                                              |
| Rivaroxaban                   | VTE prophylaxis, treatment                                                  | Oral       | Yes                                                            | Andexanet alfa | Not approved in patients with mechanical valves |
|                               | VTE prophylaxis after knee and hip replacement                              | Once-daily dosing |                                                                |          | Limited data to suggest rivaroxaban may be used in patients with a BMI > 40 kg/m^2 |
|                               | Atrial fibrillation/flutter                                                  |            |                                                                |          | Interacts with inducers/inhibitors of P-glycoprotein, CYP34A                         |

(continued on following page)
with certain DOACs relative to warfarin (1–3), DOAC use may still be complicated by life-threatening bleeding and studies have not been done on critically ill patients (4).

Before initiating a DOAC, drug- and patient-related factors must be considered. DOACs require dose adjustments in patients with kidney disease and should be avoided in those with significant renal dysfunction. Prior history of major bleeding, concurrent use of antiplatelet therapy, thrombocytopenia, and coagulation factor deficiency increase bleeding risk. In patients with planned invasive procedures, DOACs should be stopped if there is a high risk of bleeding (5).

Minor bleeding does not necessarily require interruption of DOACs, as withdrawal of the anticoagulant therapy may result in increased risk of thrombotic complications. In these cases, the patient should be monitored, and local interventions to manage bleeding can be pursued. The inability to assess drug levels and degree of anticoagulation to guide anticoagulant reversal complicates management decisions.

### MANAGEMENT OF BLEEDING IN PATIENTS ON DOACS

In cases of serious bleeding (i.e., intracerebral hemorrhage, compartment syndrome) and bleeding that requires transfusion or invasive intervention, DOACs should be discontinued and reversal of the anticoagulated state attempted. Reversal strategies may include dialysis for dabigatran removal, administration of clotting factor products such as activated prothrombin complex concentrate (PCC) or unactivated 4 factor PCC, or administration of agent-specific reversal drugs. Idarucizumab may be used to reverse the effects of dabigatran if conservative measures are ineffective in a life-threatening scenario.

**Table 3. Overview of direct oral anticoagulants (continued)**

| Name         | Indications                  | Delivery                  | Dose Adjustment or Avoidance Recommended for Renal Impairment? | Other Considerations | Reversal |
|--------------|------------------------------|---------------------------|----------------------------------------------------------------|----------------------|----------|
| Edoxaban     | VTE prophylaxis, treatment (after initial parenteral treatment) | Oral                      | Yes                                                            | Andexanet alfa       | Reversal |
|              |                              |                           |                                                                  |                      |          |
| Betrixaban   | VTE prophylaxis              | Oral                      | Once-daily dosing                                               | Andexanet alfa       |          |
|              |                              |                           |                                                                  |                      |          |

**Definition of abbreviations:** aPPT = activated partial thromboplastin time; BID = twice daily; BMI = body mass index; HIT = heparin-induced thrombocytopenia; HITT = heparin-induced thrombocytopenia and thrombosis; VTE = venous thromboembolism.
bleed or if an emergency procedure is required and thrombin time is prolonged (6). When idarucizumab is not available, PCC should be used. For severe life-threatening bleeding with factor Xa inhibitors, particularly intracerebral hemorrhage, andexanet alfa may be used (7). This medication is not readily available at most centers and cost remains prohibitive. More commonly, 4 factor PCC is administered. Both andexanet alfa and PCC increase risk of thrombosis and should only be given for significant bleeding events.

There is no high-quality evidence to endorse a particular drug reversal strategy. The risk of thrombosis in the setting of DOAC reversal must be weighed against the risk of morbidity from the bleeding event. Similarly, there is no universally endorsed guideline for transition from DOACs to continuous heparin infusions. More data are needed to guide the complex management of critically ill patients on DOACs.

REFERENCES
1. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.
4. Rajasekhar A, Beyth R, Crowther MA. Newer anticoagulants in critically ill patients. Crit Care Clin 2012;28:427–451, vii.
5. Dager W, Hellwig T. Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. Am J Health Syst Pharm 2016; 73(Suppl 2):S14–S26.
6. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511–520.
7. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al.; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326–1335.

UPPER GASTROINTESTINAL HEMORRHAGE
Geoffrey D. Bass and Cameron M. Baston

INITIAL APPROACH
The initial approach to undifferentiated upper gastrointestinal hemorrhage (UGIH) requires simultaneous diagnostic testing, hemodynamic assessment, and resuscitation.

Bedside evaluation focuses on the identification of shock and the source of bleeding. Bright red blood per rectum with hemodynamic instability is assumed to be due to massive UGIH. Clinical evaluation should include iterative assessment of hemodynamics and laboratory testing for anemia, coagulopathy, end-organ injury, and markers of cirrhosis. Endotracheal intubation for airway protection may be necessary in cases of
active hematemesis, severe shock, or encephalopathy.

Resuscitation requires robust vascular access such as two short 18-gauge or larger catheters in proximal veins or a resuscitation catheter in a central vein (1). Conventional triple lumen and peripherally inserted central catheters have increased resistance to flow owing to length and relatively narrow diameter, making them less ideal for rapid infusion. While awaiting crossmatched blood products, crystalloids or uncrossmatched packed red blood cells (PRBCs) may be used. In massive hemorrhage, transfusion is guided by hemodynamics and blood loss, not laboratory values. Although practices vary across institutions, data extrapolated from traumatology support administering a ratio of 1 unit PRBCs: 1 unit platelets: 1 unit fresh frozen plasma to minimize coagulopathy (2). Once relative hemodynamic stability is achieved, PRBC transfusion should follow a restrictive transfusion threshold of <7 g/dl, which reduces mortality and rebleeding rates, particularly in patients with cirrhosis (1). Usual practice is to correct thrombocytopenia if platelets are <50 × 10^9/L. Coagulopathy due to vitamin K antagonists should be reversed. Prothrombin complex concentrate may be preferable to fresh frozen plasma owing to lower volume and faster time of onset, higher cost notwithstanding (3).

Adjunctive initial therapy often includes a proton pump inhibitor (PPI) and octreotide, as these therapies have potential benefits without significant adverse effects. Figure 3 summarizes the management of upper gastrointestinal hemorrhage.

DIFERENTIATION OF UGIH

Timely endoscopy frequently enables diagnosis and control of UGIH. Consensus statements advocate endoscopy within 24 hours for hospitalized patients (1). In a recent study in patients with UGIH at high risk for further bleeding or death, endoscopy performed <6 hours after gastrointestinal consultation did not result in lower 30-day mortality than endoscopy performed between 6 and 24 hours after consultation (4). Achieving hemodynamic stability to tolerate sedation during endoscopy is important but does not preclude endoscopy in a hemodynamically tenuous patient requiring ongoing resuscitation.

If endoscopy is unavailable or delayed, gastric lavage and computed tomography angiography can be used to attempt to localize the source of bleeding. Gastric tube aspiration has a high false-negative rate. Computed tomography angiography is highly sensitive for detecting rapid gastrointestinal bleeding (5).

DIFFERENTIATED UGIH

Peptic ulcers are the most common etiology of UGIH and are treated with high-dose PPI to reduce the risk of rebleeding and need for endoscopic intervention. They do not have an effect on mortality (6). PPI therapy may provide hemostasis in other causes of UGIH owing to clot stabilization. Other sources of UGIH such as mucosal/erosive disease, Mallory-Weiss tear, and malignancy require an individualized approach coordinated with a gastroenterologist and surgeon.

In variceal UGIH, octreotide has been shown to help achieve hemostasis and prevent rebleeding but does not have an established mortality benefit (7). Octreotide decreases the hepatic venous pressure gradient and splanchnic vasodilation. Approximately 20% of patients with variceal UGIH have an active infection; thus, investigation for source and empiric antibiotics are recommended regardless of whether a patient has ascites.
Antibiotics decrease the rate of bacterial infection and incidence of rebleeding and improve survival (9). Antibiotic choice is typically a third-generation cephalosporin or fluoroquinolone for a maximum of 7 days. PPI is not indicated in variceal UGIH unless peptic ulcer disease is present. β-Blockers should be withheld.

RESCUE THERAPIES

In recurrent UGIH, second-look endoscopy is indicated to reattempt source identification and control. Endoscopically administered spray hemostatic agents are increasingly deployed as a temporizing measure in nonvariceal UGIH. If hemorrhage cannot be controlled, interventional radiology can often perform superselective embolization given high surgical morbidity. Surgical intervention remains an available therapy in select cases.

In variceal UGIH, bleeding cannot be controlled or recurs in 20% of patients. Balloon tamponade devices and transjugular intrahepatic portosystemic shunt (TIPS) are rescue therapies. Balloon tamponade devices provide immediate control in >80% of patients.
but use is limited to 24 hours because of the risk of esophageal necrosis (10). TIPS is highly effective in variceal UGIH. After successful endoscopy for UGIH, TIPS within 72 hours of admission is associated with lower treatment failure and mortality in selected high-risk patients (11).

REFERENCES

1. Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, et al. Diagnosis and management of nonvarical upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:a1–a46.

2. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al.; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015;313:471–482.

3. Odutayo A, Desborough MJ, Trivella M, Stanley AJ, Dorée C, Collins GS, et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol 2017;2:354–360.

4. Lau JW, Xu Y, Tang RSY, Chan HCH, Yip HC, Chan SM, et al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med 2020;382:1299–1308.

5. Wu LM, Xu JR, Yin Y, Qu XH. Usefulness of CT angiography in diagnosing acute gastrointestinal bleeding: a meta-analysis. World J Gastroenterol 2010;16:3957–3963.

6. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005;330:568.

7. Gotzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices. Cochrane Database Syst Rev 2000; (2):CD000193.

8. Bleichner G, Boulanger R, Squara P, Sollet JP, Parent A. Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage. Br J Surg 1986;73:724–726.

9. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011;34:509–518.

10. Avgierinos A, Armonis A. Balloon tamponade technique and efficacy in variceal haemorrhage. Scand J Gastroenterol Suppl 1994;207:11–16.

11. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management. 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310–335.

VASOPRESSOR SELECTION

Steven D. Pearson and Krysta S. Wolfe

OVERVIEW

Vasopressor medications are a cornerstone of treatment in shock. They are indicated when tissue perfusion remains insufficient despite adequate intravascular volume resuscitation. Vasopressors restore tissue perfusion predominantly through vasoconstriction, although many also increase cardiac contractility (Table 4). Despite their longstanding and widespread use in critical care, data supporting the use of a single vasopressor over another remain limited.
CATECHOLAMINES

Catecholamines are the most common vasopressor and inotropic agents used in the treatment of shock. Historically, both dopamine and norepinephrine were recommended as first-line agents. In 2010, the SOAP II (Sepsis Occurrence in Acutely Ill Patients) trial was published comparing dopamine and norepinephrine in 1,679 patients with shock. There was no mortality difference between groups, but dopamine was associated with increased adverse events, primarily arrhythmias. Subgroup analysis of patients with cardiogenic shock showed increased mortality in the dopamine group (1). A subsequent meta-analysis of 11 studies comparing dopamine with norepinephrine in septic shock found dopamine to be associated with increased mortality and arrhythmias (2). Data on the use of phenylephrine in septic shock and clinical outcomes are limited, although small studies have suggested similar performance when compared with norepinephrine (3). Epinephrine is most often used in the treatment of anaphylactic shock. It has similar hemodynamic effects to norepinephrine but results in transient lactic acidosis and a higher rate of arrhythmias (4). Based on the available data and expert opinion, norepinephrine is considered the first-line vasopressor for the management of septic shock (5). This is supported by observational data from a 2011 U.S. norepinephrine shortage that revealed an increase in septic shock mortality in affected hospitals, with phenylephrine and dopamine being the most commonly used alternative

| Vasoactive | Receptor Activity | CO | SVR | Indications | Adverse Effects | Usual Dose Range |
|------------|------------------|----|-----|-------------|----------------|-----------------|
| Phenylephrine | $\alpha_1$ | ↔ | ↑↑ | Alternative to $\beta_1$ agonists | Reflex bradycardia | 0.5–6 mcg/kg/min |
| Norepinephrine | $\alpha_1 > \beta_1$ | ↔/↑ | ↑↑ | Septic shock, cardiogenic shock | Tachyarrhythmias | 0.025–0.3 mcg/kg/min |
| Epinephrine | $\alpha_1 = \beta_1 > \beta_2$ | ↑↑ | ↑↓ | Anaphylactic shock, bradycardia, cardiogenic shock | Tachyarrhythmias, splanchnic vasoconstriction | 0.01–0.7 mcg/kg/min |
| Dopamine | — | — | — | Relative or absolute bradycardia and low risk for tachyarrhythmias | High rate of tachyarrhythmias | 2–20 mcg/kg/min |
| Low | DA $> \beta_1$ | ↑ | ↔ | | | |
| Medium | DA $= \beta_1 > \alpha_1$ | ↑ | ↑ | | | |
| High | $\beta_1 > DA = \alpha_1$ | ↑↑ | ↑↑ | | | |
| Dobutamine | $\beta_1 > \beta_2$ | ↑ | ↓ | Cardiogenic shock | Tachyarrhythmias, hypotension | 2–20 mcg/kg/min |
| Vasopressin | $V_12$ | ↔ | ↑ | Second line for septic shock, may reduce atrial fibrillation | Mesenteric ischemia at higher doses | 0.01–0.07 mcg/kg/min |
| Angiotensin II | AT$_1$ | ↔ | ↑ | Refractory septic shock | Thrombosis | 10–40 ng/kg/min |
| Methylenedioxy | Inhibits NOS and sGC | ↔ | ↑ | Refractory vasoplegia | Hemolysis, serotonin syndrome | 1.5–2 mg/kg over 20–60 min |

**Table 4.** Commonly used vasoactive medications and their receptor activity, physiologic effects, and relevant clinical information

*Definition of abbreviations: $\alpha_1$ = alpha-1 receptor; AT$_1$ = angiotensin II receptor type 1; $\beta_1$ = beta-1 receptor; $\beta_2$ = beta-2 receptor; CO = cardiac output; DA = dopamine receptor; NOS = nitric oxide synthase; sGC = soluble guanylate cyclase; SVR = systemic vascular resistance, $V_2$ = vasopressin receptor 2.*
vasopressors (6). In cardiogenic shock, the use of agents with greater inotropic properties, such as dobutamine, is often required.

**VASOPRESSIN**

Vasopressin is commonly used as a second-line agent in the treatment of vasodilatory shock. The VASST (Vasopressin and Septic Shock Trial) trial compared norepinephrine alone with norepinephrine plus vasopressin in 778 patients with septic shock and found no difference in mortality (7). In the VANISH (Ventricular Tachycardia Ablation versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease) study, a comparison of norepinephrine plus hydrocortisone or placebo and vasopressin plus hydrocortisone or placebo, there was no difference in kidney failure–free days or mortality (8). The use of vasopressin is recommended as an additional agent in refractory vasodilatory shock or with the intent of reducing the dose of catecholamine used (5). The latter use is supported by meta-analysis data demonstrating lower rates of atrial fibrillation when vasopressin was used with catecholamine vasopressors compared with catecholamines alone (9).

**ANGIOTENSIN II**

Angiotensin II has emerged as a novel noncatecholamine vasopressor for treatment of vasodilatory shock. The ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) trial, a randomized controlled clinical trial including patients with vasodilatory shock receiving high-dose norepinephrine, demonstrated that angiotensin II was effective at increasing mean arterial pressure and was well tolerated when compared with placebo (10). Angiotensin II is a promising third-line vasopressor after norepinephrine and vasopressin, as all three agents have differing mechanisms of action, although further study is needed before widespread adoption.

Author disclosures are available with the text of this article at www.atsjournals.org.

**REFERENCES**

1. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al.; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010;362:779–789.

2. De Backer D, Aldecoa C, Njimi H, Vincent J-L. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*. *Crit Care Med* 2012;40:725–730.

3. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Laderchi A, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. *Crit Care* 2008;12:R143.

4. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J; CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. *Intensive Care Med* 2008;34:2226–2234.

5. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. 2016. *Crit Care Med* 2017;45:486–552.

6. Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association between US norepinephrine shortage and mortality among patients with septic shock. *JAMA* 2017;317:1433–1442.
7. Russell JA, Walley KR, Singer J, Gordon AG, Hébert PC, Cooper DJ, et al.; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008;358: 877–887.

8. Gordon AC, Mason AJ, Thirunavukarasu N, Perkins GD, Cecconi M, Cepkova M, et al.; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. *JAMA* 2016;316:509–518.

9. McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. *JAMA* 2018;319:1889–1900.

10. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al.; ATHOS-3 Investigators. Angiotensin II for the treatment of vasodilatory shock. *N Engl J Med* 2017;377:419–430.